Q2
COLL — Q2 2026 Financial Report Analysis
Collegium's Q2 2026 revenue rose 6.3% to $199.9M on Jornay PM (+41%) and the new Azstarys deal, but deal costs drove a $15.1M GAAP loss and Nucynta generic erosion forced a $40M cut to full-year revenue guidance.